C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD

Olorunfemi A Oshagbemi, Frits M E Franssen, Emiel F M Wouters, Anke H Maitland-van der Zee, Johanna H M Driessen, Anthonius de Boer, Frank de Vries*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

AIMS: C-reactive protein (CRP) is an important biomarker in systemic inflammation in COPD; reports have suggested inhaled corticosteroids (ICS) attenuate CRP levels. We evaluated the risk of moderate-to-severe exacerbations, severe exacerbations and all-cause mortality among patients with COPD currently exposed to Inhaled corticosteroids (ICS) stratified by CRP levels compared to never ICS users with low CRP levels.

METHODS: We included subjects age 40 or more who had a diagnosis of COPD from January 1, 2005 to January 31, 2014 from the UK Clinical Practice Research Datalink (CPRD). ICS exposure was determined time-dependently, as current, recent, past or never users. We evaluated the risk of moderate-to-severe exacerbations, severe exacerbations and all-cause mortality among ICS users stratified by CRP levels.

RESULTS: 17,722 subjects diagnosed with COPD met the inclusion criteria. Among current or never ICS with elevated CRP levels we found, no significantly reduced risk of moderate-to-severe or severe exacerbations. For patients currently exposed ICS with CRP levels ≥8 mg/L there was no reduced risk of moderate-to-severe exacerbations (adjusted hazard ratio [adj. HR] 0.99; 95% confidence interval [CI] 0.76-1.31) or severe exacerbations (adj.HR 1.52; 95% CI 0.71-3.27). However, we found an increased risk of all-cause mortality among COPD patients with CRP levels ≥8 mg/L irrespective of ICS exposure.

CONCLUSION: We did not find a reduced risk of moderate and/or severe COPD exacerbations among COPD patients with varying CRP levels currently exposed to ICS. However, low-grade systemic inflammation was associated with all-cause mortality among COPD patients.

Original languageEnglish
Article number101870
Pages (from-to)101870
Number of pages7
JournalPulmonary Pharmacology & Therapeutics
Volume60
Early online date27 Nov 2019
DOIs
Publication statusPublished - Feb 2020

Keywords

  • C-reactive protein
  • CARDIOVASCULAR-DISEASE
  • CIGARETTE-SMOKING
  • COMORBIDITIES
  • Chronic obstructive pulmonary disease
  • EXACERBATION
  • Exacerbations
  • FLUTICASONE
  • INFLAMMATION
  • Inhaled corticosteroids
  • MODERATE
  • MORTALITY
  • OBSTRUCTIVE PULMONARY-DISEASE
  • RISK

Cite this